Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Core Insights - Korro Bio, Inc. is focused on developing a new class of genetic medicines through RNA editing for both rare and prevalent diseases [1][4] - The company will present its first development candidate, KRRO-110, aimed at treating alpha-1 antitrypsin deficiency (AATD) at the upcoming Oligonucleotide Therapeutics Society meeting [2][3] Company Overview - Korro Bio utilizes a proprietary RNA editing platform to create genetic medicines that allow for precise and transient single base edits, expanding the potential of genetic therapies [4] - The company aims to leverage established delivery methods, manufacturing expertise, and regulatory pathways associated with approved oligonucleotide drugs to bring its therapies to market [4] Presentation Details - Venkat Krishnamurthy, Ph.D., will deliver an oral presentation on KRRO-110 on October 7, 2024, at 3:20 p.m. ET [3] - Two poster presentations will also be featured, focusing on the evaluation of RNA editing in a cell-free environment and the behaviors of RNA editing oligonucleotides [3]